Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
– Clinical stage biopharmaceutical company completes upsized, oversubscribed Series D financing from leading life sciences investors – CHICAGO—November 3, 2022 – Emalex Biosciences announced [...]
Outstanding First Half for Paragon and its Portfolio Companies
Paragon and its portfolio companies continue to successfully advance biology-based innovation, creating impressive results. First Half 2022 Newsletter We are a [...]
Castle Creek Biosciences Raises $112.8 Million to Advance Novel Gene Therapies and Expand Pipeline
– Funding expected to provide sufficient capital for completion of Phase 3 trial for ex vivo product candidate for recessive dystrophic epidermolysis bullosa and [...]
Evozyne Announces Multi-Target Research Collaboration and License Agreement with Takeda to Develop Next-Generation Gene Therapies
Expansion builds on initial strategic collaboration and license agreement Chicago, April 5, 2022 – Evozyne, Inc., an adaptive biology company [...]
Emalex Biosciences Expands CNS Platform to Advance Treatment for Restless Legs Syndrome with Augmentation
License agreement secures potential research of ecopipam for one of the most common neurological sensory disorders Chicago, March 1, 2022 – Emalex Biosciences, Inc. (“Emalex”), [...]
Outstanding 2021 for Paragon Biosciences and Our Portfolio Companies
Chicago, Dec. 16, 2021 – Paragon Biosciences has had a stellar year of achievements in 2021, advancing our mission to solve some of society’s most [...]
